Moreover, classifying cancers into T cell-inflamed tumors (PD-L1 high, CD8 high, and IFN-γ signature) versus noninflamed tumors (immune-excluded and immune-desert), is proving to be possible to predict survival rate based on the immune checkpoint inhibitor (ICI) responses. The gene discussed is CD274; the disease is cancer.